The European Commission released a roadmap for its planned revision of pharmaceutical legislation for next year. With the adoption of the new strategy, which is “intended to make the European pharmaceutical system patient-centered, future-proof and crisis-resistant” according to the Commission, the regulatory body has also pledged that by the end of 2022, Directive 2001/83/EC and Regulation (EC) No 726/2004 will be revised. The Commission writes, “The EU pharmaceuticals system should ensure the quality and safety of medicines, while boosting the sector’s global competitiveness and creating a regulatory environment, which is attractive for innovation and investment and supported by international harmonised standards and, where possible, regulatory convergence.”
Read more here.